Hypertension is greatly related to Alzheimer's disease

Researchers at the Feil Family Brain and Mind Research Institute in New York recently published an article in the Journal of Clinical Investigation revealed that hypertension affects neurovascular regulation and recognition in the brain. Through research using recombinant human proteins, The mechanism of perivascular macrophage (PVM) has been found to play a key role in this process.

Studies have shown that long-term (14-day) infusion of ANGII in mice can cause a slow increase in blood pressure (to model hypertension) and cause brain neurovascular dysregulation, whereas the latter may affect brain recognition Knowledge function.

The researchers found that perivascular macrophages play an important role in the above-mentioned alterations in function, which is necessary for ANGII to cause neurovascular regulatory mechanisms. When mice were infused with ANGII for a long time, ANGII could cross the blood-brain barrier and enter the perivascular space. At this time, ANGII can bind to the ANGII-type receptor (AT1R) on the perivascular macrophage surface, enabling the latter to activate the NOX2-type NADPH oxidase, thereby catalyzing the production of reactive oxygen species (ROS) and causing damage to the brain Oxidative Stress in Regulatory Mechanism of Neurovascular. In contrast, short-term rapid infusion did not allow ANGII to cross the blood-brain barrier.

In order to better simulate human hypertensive conditions, the researchers used a chronic hypertensive mouse model strain BPH / 2J experiments. These mice have significant brain neurovascular regulatory mechanism abnormalities and cognitive dysfunction. The results showed that when the perivascular macrophages were clodronate clearance, the AT1R was blocked or ROS was cleared and the neurovascular regulatory mechanism abnormalities would be significantly reduced; perivascular macrophage clearance is more significantly to improve the cognitive function of mice.

This study shows that perivascular macrophages in the case of hypertension can occur under the oxidative stress caused by the inflammatory response, causing the brain neurovascular regulatory mechanisms and cognitive abnormalities of the brain, and it suggests that perivascular macrophages as the potential target of drugs are expected to reduce brain function due to high blood pressure and damage. Flarebio offers good-quality recombinant proteins such as recombinant PIGR for your research.

To treat rheumatic arthritis in a new way

A study led by researchers at the University of Birmingham reveals the key role of different types of fibroblasts in the development of rheumatoid arthritis (RA) using recombinant horse proteins, opening a new avenue for therapeutic research in this disease. Synovial fibroblasts (SFs) are cells that form part of the connective tissue or synovium, or artificial joint. In patients with rheumatoid arthritis, SF cells invade and attack cartilage and bone around the joint, causing injury.

A group of researchers at the Institute of Inflammation and Aging at the University of Birmingham identified two different types of SF cells within the synovial membrane. The team showed that these cell types (defined by the presence of specific cell surface markers PDPN and CD248) were aggregated in different layers of the synovium, and only one (PDPN typing) resulted in cartilage damage in RA patients.

During the course of the study, SF cells from RA patients were grown in an artificial synovium in vitro and then activated using stress-induced proteins called cytokines. An artificial synovial membrane containing SFs migrates into mice (whose own immune system has been "shut down"), while moving into human cartilage to mimic joints and see how SF cells develop in the body. After implantation, the test showed that the "lining" layer of the artificial synovium (i.e., closest to the cartilage portion) contained invasive PDPN-type SFs, while the distal part of the cartilage contained non-invasive CD248 typing.

The study also confirmed a recent finding that "activated" SF cells can migrate, that is, through the blood vessels to attack other in vivo cartilage. On the basis of these findings, the researchers showed that PDPN-typed SF cells migrated first and that CD248 cells only appeared in secondary tissues at later stages.

"This study not only shows the presence of different subtypes of synovial fibroblasts, but also suggests that these cells are able to self-infiltrate into the ‘lining’ and ‘sub-lining’ layers of the cartilage," said Dr. Adam Croft of the University of Birmingham who led the study. ”Combining the differences in cell mobility between the two cell types, these results have great potential in finding new therapeutic targets for rheumatoid arthritis."

The current treatment of RA is mainly to the patient immunosuppressive drug combination, may seriously affect the quality of life. The results of this study show that the SF cell process for the method not only make future treatment more effective but more easily accepted by patients. Flarebio offers superior recombinant proteins like recombinant Aoc3 at great prices.

The discovery and development of target probe of proteins

As one of the most abundant biological macromolecules, protein is the main performer of biological function and plays a key role in all kinds of life activities. Scientists have been exploring the application of protein manipulation tools in the living environment through recombinant human proteins in order to achieve the goal of protein structure and function of in-depth study, which has become one of the frontiers of the field of chemical biology. Many research groups in China have realized the specific activation of proteins through chemical decoupling technology, two-photon and near-infrared control technology and targeted small molecule probes and studied the molecular mechanism of cell signal transduction process.

In the field of chemical decoupling technology, Chen Peng's group put forward a new strategy of rational design of small molecule activator by combining non-natural amino acid fixed-point insertion technology and biological orthogonal "chemical decoupling" reaction. For example, protein kinase-mediated phosphorylation is a key process in cellular signal transduction and has a major influence on most physiological activities. However, the molecular mechanism of many kinases under normal physiological and pathological conditions is unclear. The use of small molecule activators can be used in kinase signaling studies to obtain new information. "We activate the 'effector protein OspF' in living cells and found that this protein causes 'phosphorylated Erk protein' in the nucleus to undergo a 'nuclear transport' mediated by irreversible dephosphorylation," said Chen.

In recent years, protein light-control technology has become another powerful tool to study cell signal transduction. Compared with the UV-excited probe, the two-photon-excited probe can greatly reduce the cytotoxicity and has broad application prospects. Liu Lei group from Tsinghua University took protein synthesis as the core technology to develop targeted immune protein light-control probe and made use of newly-developed protein probe of the immune cells in precise space-time stimulation of directional movement. This probe will provide an ideal molecular tool for understanding and controlling cell localization and localization-related cellular life activities in living tissue. Chen Xing group from Peking University has developed the use of near-infrared light activation and regulation of cell signal transduction pathway of the new method.

Yang Yi, a research group of East China University of Science and Technology used the natural photosensors to construct a light-controlled gene expression system for the targeted protein production and degradation. In the experiment, the researchers used the light to the live cells or the living animal protein production level carries precise control on time and space, successfully controlling the production of the insulin in diabetes mellitus body and the blood sugar concentration.

Li Yanmei research group from Tsinghua University used adjustable protein degradation strategy to achieve the target protein level within the cell decreased in order to achieve the purpose of reducing its activity. The researchers focused on the phenomenon of abnormal "non-enzymatic protein Tau" in the brain of Alzheimer's disease and used the "recognition-cutting" strategy to control the content of these proteins in cells. Flarebio provides you with good-quality recombinant proteins including recombinant TLR2 at good prices.

Scientists synthesize an antitumor compound to fight chemoresistance-resistant cancers

A team of Russian scientists led by Professor Alexander Kiselyov of MIPT has synthesized an antitumor compound that can be used to fight chemoresistance-resistant cancers. The results were published in the European Journal of Medicinal Chemistry, which also publishes some other studies on recombinant horse proteins.

Scientists have synthesized a range of new compounds and evaluated their anticancer effects using sea urchin embryos and human cancer cells. One of the molecules proved to be effective and selectable, it was even sufficient for the effect of chemically-resistant ovarian cancer. The synthesized compound is known as amino isothiazoles. "We decided to validate the aminoisothiazoles because these compounds exhibit different pharmacological and biological activities, which are the functional groups we expect to use as anticancer agents," said Professor Alexander Kiselyov.

The proposed method can directly synthesize the target compound in high yield. The reaction sequence involves only six steps, and the reagents are readily available. To evaluate their antitumor activity, the researchers used in vitro assays based on human cancer cells, as well as embryonic models of sea urchin in vivo previously developed and validated by the team.

Among the 37 synthesized compounds, 12 of these molecules have different potency to reduce the rate of proliferation of cancer cells or prevent them from dividing completely, leading to cancer cell death. The action of these anti-tumor compounds is due to their ability to destroy microtubules involved in cell division (mitosis). Microtubules are made of proteins called tubulin, which can be targeted by anticancer agents, causing microtubule structure degradation.

The efficacy of synthetic compounds targeting microtubules was further evaluated using sea urchin embryos and a panel of human cancer cells from breast, melanoma, ovarian and lung tumors. Sea urchin embryos have been shown to be good models for studying specific tubulin binders. They make the embryo to rotate rapidly, rather than moving in the usual way. This effect can be easily observed using an optical microscope, allowing the scientists to evaluate the anticancer potential of the compound in a short time.

In addition, the team found that sea urchin embryos are more sensitive to drugs than cancer cells. The difference between the duration of the mitotic cycle of sea urchin embryos and cancer cells (40 minutes to 24 hours) may lead to different effects of small molecules on the tubulin kinetics, thus explaining this phenomenon. According to the researchers, it is this combination of functional groups, as well as the unique properties of molecules, that determines its unique activity. In particular, the new drug shows anti-tubulin properties because it destroys chemically-resistant cells of ovarian cancer by affecting microtubules to block cell division.

Scientists plan to study microtubule degradation in more detail using crystallographic data and structural modeling techniques to determine where the active compound binds to tubulin. In their earlier work, researchers used substances isolated from seeds of dill and parsley to synthesize another anti-cancer compound, glaziovianin A and its structural analogs. Flarebio provides you with recombinant proteins of good quality such as recombinant ITGB5.

Intestinal bacteria can reduce the risk of obesity and type 2 diabetes

The intestinal bacteria Akkermansia has been shown through recombinant mouse proteins to provide lasting benefits to overweight mice and to the intestine of diabetic animals. In the experiment, even after the pasteurization, the bacteria on the intestinal barrier strengthening effect still exist. These are the conclusion obtained by researchers at the Louvain Institute for Drug Research at the University of Louvain and researchers at the University of Wageningen and researchers at the University of Helsinki in Nature Medicine on November 28. Their results help to pave the way for the treatment of diabetes and obesity, but also for the treatment of cardiovascular disease and gastroenteritis.

In obese mice, the Patrice Cani group led by Willem M. De Vos and the Helsinki team led by Wageningen found that Akkermansia is able to prevent obesity and progress in type 2 diabetes in mice. The intestinal bacteria Akkermansia muciniphila found in mice has special effects on obesity and type 2 diabetes.

The Leuven group identified that Akkermansia's active form can reduce the effects of obesity and diabetes. Their team has confirmed that even after pasteurization - heating above 70 degrees Celsius, Akkermansia still prevents the disease from developing in mice. Pasteurization is attempted to inactivate the bacteria without destroying its properties. However, in its inactive state, bacteria continue to be effective against disease. "This is a surprising surprise," said William Devos. Even more shocking is that bacteria part become more active after the pasteurization. It not only reduced obesity and diabetes, but also prevents further development of these diseases.

The effectiveness of Akkermansia is greatly due to its inhibition of enteritis, such as enteritis or chronic irritable bowel syndrome. The applicability of intestinal bacteria to patients with obesity and diabetes is currently being tested in Brussels. The results are still expected, but the first clinical trial on the safety of the administration of intestinal bacteria in inactivated form was positive.

The team found that the unintended effect of pasteurized Akkermansia bacteria was due to the protein in the outer membrane of bacteria and was studied in the Wageningen team by Dr. Noora Ottman and Dr. Clara Belzer. This protein - Amuc_1100 * - maintains its function after being heated. Pasteurization inactivates the bacteria as a whole, not just the functional membrane proteins. The isolation of the protein makes it possible to develop drugs in concentrated form, which can also be used in the treatment of intestinal inflammation due to stress, alcoholism, liver disease and cancer.

Researchers have applied for multiple patents on their findings. In addition, separation companies are being developed to expand the production of Akkermansia bacteria and proteins. By the way, Flarebio offers good-quality recombinant proteins such as recombinant ITGB5 for your research.

ALS mice model contributes the study of ALS

Amyotrophic lateral sclerosis (ALS), also known as Luigarella, is a fatal progressive neurological disease that attacks nerve cells that control free muscles. At present, no effective treatment has been found.

Scientists have been using animal models and recombinant rat proteins to understand the causes of ALS and to conduct therapy tests for decades. Most ALS investigators used a model of a transgenic mouse that mimics clinically worsening in human ALS. However, the model has a serious limitation: there is no expression of TDP-43 protein in the cell at an abnormal site aggregation, while this problem is almost present in all ALS patients. Scientists are concerned that their use of the model will miss vital details.

Now, researchers at the University of Maryland School of Medicine (UM SOM) have for the first time developed two mouse models of the pathology of this protein, TDP-43. The two mouse models also show clinical and pathological features that are visible in many ALS patients. Researchers say the new findings will open up new paths for ALS research, which affects 12,000 Americans a year.

"These new models give us a better chance to understand this disease more precisely and ultimately develop new therapies that will help ALS patients," said Dr. Mervyn Monteiro, professor of anatomy and neurobiology at the UMSOM Center for Biomedical Engineering and Technology. Dr. Monteiro and his colleagues developed these models. The paper was published in the latest issue of the Proceedings of the National Academy of Sciences (PNAS).

Dr. Monteiro has developed a new model by introducing a human gene called ubiquilin2 into mouse DNA. The normal ubiquilin2 gene creates a protein that helps to remove damaged proteins from cells. In the ALS, mutations in the gene produced by the protein can't play this function. Failure to remove damaged proteins can kill cells and cause disease. There is growing evidence that defects in the removal of damaged proteins can lead to neurodegenerative diseases, including ALS.

For three years, Dr. Monteiro and his colleagues have been studying these new ALS mouse models. To ensure that ALS symptoms in mutated mice were due to mutations in ubiquilin 2, the researchers also developed mice bearing the normal human ubiquilin 2 gene. They found that mice carrying the mutant ubiquilin 2 gene developed ALS symptoms and TDP-43 pathology. By contrast, mice carrying the normal version of the gene didn't show these problems. Mutant mice exhibit classical ALS characteristics, including progressive myasthenia gravis and loss of nerve cells that control muscle. These mice also have shorter lifespan than normal mice.

The exact cause of protein accumulation in ALS remains a mystery. However, because it occurs in almost all cases of ALS, scientists believe that it plays an important role in the disease. Dr. Monteiro said new animal models could be used to further understand how defects in protein processing lead to ALS. Ultimately, he says that this new knowledge may help to improve the overall process of removing damaged proteins, stopping or delaying the disease. Flarebio provides recombinant proteins of good quality such as recombinant NPP1 at great prices.

β-amyloid deposits are also found in heart f AD patients

In a small study using recombinant human proteins, patients with Alzheimer's disease had β-amyloid deposits in their heart tissue, and these patients also showed impaired myocardial function. The study was published in the Journal of the American College of Cardiology on December 6, 2016.

Four patients with Alzheimer's disease were detected Federica del Monte and colleagues at Beth Israel deaconess medical center in Boston and found that both β-amyloid-40 and β- amyloid-42 existed in myocardial cells and myocardial interstitium. At the same time, the study found that the absence of Alzheimer's disease control group of cardiac tissue showed no β-amyloid deposition.

In addition, linear regression analysis showed that patients with Alzheimer's disease had worse diastolic function at an early stage. "Alzheimer's disease and heart disease are both debilitating and life-threatening diseases that affect a large population of patients," del Monte and colleagues write. "Our research emphasizes the need for new diagnostic methods and treatments for previously excluded problems of brain and heart disease."

"We provide new evidence that the heart and brain can be affected in the same clinical setting, and we found that diastolic dysfunction is an early defect in patients with Alzheimer's disease and that intramyocardial amyloid deposition is present in these patients myocardium and the beta-amyloid pre-amyloid oligomers can affect heart and brain cell function and may lead to cardiac insufficiency in the study."

"Although these findings need to be validated in large populations, this study provides an interesting and possible paradigm shift in our understanding of highly pathologic and largely incurable diseases." Brian C. Jensen and Monte S. Willis at University of North Carolina at Chapel Hill wrote in an accompanying editorial. Flarebio offers good-quality recombinant proteins including recombinant CDH11 at competitive prices.